From cell biology to therapy: Forodesine

Haematologica Meeting Reports

Volumn 2, Issue 5, 2008, Pages 106-111

  Duvic, M ^a  

^a University of Texas Health Science Center at Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BEXAROTENE; CYCLOSPORIN A; DEOXYGUANOSINE; DEOXYGUANOSINE TRIPHOSPHATE; FLUDARABINE; FORODESINE; GEMCITABINE; NELARABINE; PURINE NUCLEOSIDE PHOSPHORYLASE; RASBURICASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LEUKEMIA; CANCER CELL; CELL PROLIFERATION; CELLULITIS; CLINICAL TRIAL; CONFERENCE PAPER; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; INFECTION; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PERIPHERAL EDEMA; PROPHYLAXIS; PRURITUS; RASH; REFRACTORY PERIOD; SEZARY SYNDROME; SIDE EFFECT; T CELL LEUKEMIA; T LYMPHOCYTE; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; VISUAL ANALOG SCALE;

EID: 54249153186     PISSN: 19707339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Bantia S, Ananth SL, Parker CD, Horn LL, Upshaw R. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int Immunopharmacol 2003;3:879-87.
2. Bantia S, Kilpatrick JM. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr Opin Drug Dis Dev 2004;7: 243-7.
3. Bantia S, Miller PJ, Parker CD, Ananth SL, Horn LL, Babu YS, et al. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777. Int Immunopharmacol 2002;2:913-23.
4. Bantia S, Miller PJ, Parker, CD, et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)-a novel potent and orally active immunosuppressive agent Int Immunopharmacol 2001:1:1199-210.
5. Duvic M, Forero-Torres A, Foss F, Olsen EA, Kim Y, Bennett JC, et al. Oral Forodesine (BCX-1777) is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study. "Oral forodesine (BCX-1777) is clinically active in refractory cutaneous T-cell lymphoma: results of a Phase I/II Study. Blood 2006;108:[abstract 2467], 698a.
6. Duvic M, Foss F, Olsen E, Forero-Torres A, Bennett C, Bantia S, et al. "Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma. Blood 2004;103:[Abstr 2491], 683a.
7. Duvic M, Foss FM. Mycosis fungoides: pathophysiology and emerging therapies Semin Oncol 2007;34:(6 Suppl 5):S21-8.
8. Furman RR, Gandhi VV, Bennett JC, et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia. Blood 2004;104:[abstract 2743], 750a.
9. Furman RR, Hoelzer D. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies. Semin Oncol 2007;34(6 Suppl 5):S29-34.
10. Furman RR, Iosava G, Isola L, Ravandi F, et al. Forodesine (Fodosine™), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients (Phase III study). Blood 2005;106:[abstract 881], 533a.
11. Galmarini CM, Popowycz F, Joseph B (2008) Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy Curr Med Chem 2008;15:1072-82
12. Gandhi V, Balakrishnan K. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent Semin Oncol 2007;34(6 Suppl 5): S8-12.
13. Gore L, Stelljes M, Quinones R. Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect? Semin Oncol 2008;35:92.
14. Huang M, Wang Y, Gu J, Yang J, Noel K, Mitchell BS, et al. Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H Leuk Res [Epub 2008 Feb 14] 2008;32:1268-78.
15. Isola L, Furman, RR Gandhi, V et al. Antileukemic activity and pharmacodynamics of intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, in phase I/II trials in patients with advanced T-cell malignancies Blood 2004;104: [abstract 4501], 208b.
16. Kicska G A, Long L, Horig H, et al.Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase selectively inhibits human T lymphocytes Proc Nat Acad Sci USA 2001;98:4593-8.
17. Korycka A, Lech-Marada E, Robak T (2008) Novel purine nucleoside analogues for hematological malignancies Recent Patents Anticancer Drug Discov 2008;3:123-36.
18. Miles RW, Tyler PC, Furneaux RH, et al. One-third-the-sites transition-state inhibitors to purine nucleoside phosphorylase Biochemistry 1998;37:8615-21.